Efficacy of Ultraviolet Germicidal Irradiation (UVGI) Devices to Decrease the Incidence of Respiratory Infections in Nursing Homes : a Cluster Randomized Crossover Trial
Launched by CENTRE HOSPITALIER EMILE ROUX · Aug 21, 2024
Trial Information
Current as of August 22, 2025
Recruiting
Keywords
ClinConnect Summary
The RESPROTECT trial is studying how effective special devices that use ultraviolet light (UVGI) are at reducing respiratory infections in older people living in retirement homes. Researchers want to find out if retirement homes equipped with these UVGI systems experience fewer cases of upper and lower respiratory infections during winter compared to homes without these devices. This study will take place over two winter seasons and will involve several retirement homes working together.
To be eligible for the trial, retirement homes must have had regular cases of respiratory infections in the past winters and agree to follow the study's guidelines. They also need to be willing to install the UVGI devices. Residents, or their legal guardians, will be informed about the study and must agree to share some health information for the research. It's important to note that homes already using other air treatment systems like HEPA filters cannot participate. If your loved one lives in a retirement home that meets these criteria, they might be part of this important study aimed at improving health for older adults.
Gender
ALL
Eligibility criteria
- Center Inclusion criteria:
- Elderly Nursing homes (ENH):
- • Having a system for monitoring cases of upper and lower respiratory infections among their residents.
- • Agreeing to take part in the study
- • Undertaking to comply with the protocol
- • Accepting the installation of UVGI devices
- • Undertaking to provide all residents or their legal guardians/curators with an individual information leaflet.
- Center Non-inclusion criteria:
- ENH:
- • Not wishing to be equipped with UVGI devices in all rooms considered necessary to be equipped by the investigators
- • Having planned a major change to the structure (extension, renovation, closure, requalification, etc.) during the course of the study, which could affect the study population and/or UVGI air treatment devices.
- • Individual eligibility criteria
- Individual Inclusion criteria:
- • All residents present in one of the participating ENH at the start of each of the two study periods, or arriving in one of the participating ENH during one of the two periods, will be eligible
- Individual Non-inclusion criteria :
- • Residents of the ENH included in the study who have expressed (personally or through a relative or legal representative) the wish that their personal data not be used for the study will not be included in the study.
About Centre Hospitalier Emile Roux
Centre Hospitalier Émile Roux is a leading healthcare institution dedicated to advancing medical research and improving patient care through innovative clinical trials. Located in France, the hospital is committed to conducting rigorous scientific studies that enhance understanding of various health conditions and contribute to the development of new treatment modalities. With a multidisciplinary team of experienced researchers and healthcare professionals, Centre Hospitalier Émile Roux prioritizes patient safety and ethical standards, ensuring that all clinical trials are conducted in accordance with regulatory guidelines. The institution's collaborative approach fosters partnerships with academic institutions and industry stakeholders, positioning it as a pivotal player in the field of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Le Puy En Velay, , France
Craponne Sur Arzon, , France
Beaulieu, , France
Espaly Saint Marcel, , France
Langeac, , France
Le Monastier Sur Gazeille, , France
Le Puy En Velay, , France
Le Puy En Velay, , France
Le Puy En Velay, , France
Monistrol Sur Loire, , France
Sainte Sigolène, , France
Saugues, , France
Vorey, , France
Patients applied
Trial Officials
Cyril CORNILLE, MD
Principal Investigator
Hôpital Emile Roux, le Puy en Velay
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported